Anthropic laid out plans to use its Claude large language model to target bottlenecks across clinical development, including study design assessment and manufacturing-document automation. The company cited work with Bristol Myers Squibb, where Claude is used to analyze proprietary early-stage data and help generate clinical study plans. Anthropic also described a collaboration with Enveda in which Claude flagged issues across manufacturing documentation, reducing average document review time from about 25 hours to under three hours across a test set of 1,061 pages. For biopharma teams, the initiative frames AI as process infrastructure for speed and consistency—while it remains dependent on real-world validation and integration into existing trial and quality-management workflows.